Last reviewed · How we verify
Arthritic Pain — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Qutenza | CAPSAICIN | Averitas | capsaicin | Transient receptor potential cation channel subfamily V member 1 | 2009-01-01 | |
| Salonpas | METHYL SALICYLATE | Hisamitsu Pharm Co | methyl salicylate | 2008-01-01 | ||
| Acetaminophen | Paracetamol | Polymedica | acetaminophen | Transient receptor potential cation channel subfamily V member 4 | 1968-01-01 | |
| Norgesic | acetylsalicylic acid | Endo | centrally acting muscle relaxant with anticholinergic properties | reticular formation (brain stem) | 1950-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Arthritic Pain
- Averitas · 1 drug in Arthritic Pain
- Endo · 1 drug in Arthritic Pain
- Hisamitsu Pharm Co · 1 drug in Arthritic Pain
- Polymedica · 1 drug in Arthritic Pain
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Arthritic Pain:
- Arthritic Pain treatment updates — RSS
- Arthritic Pain treatment updates — Atom
- Arthritic Pain treatment updates — JSON
Cite this brief
Drug Landscape (2026). Arthritic Pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/arthritic-pain. Accessed 2026-06-10.
Related
- Arthritic Pain full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing